Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Anthem

Bristol-Myers

Elanco Animal Health Inc

The Vanguard Health Care Fund (Trades, Portfolio) recently disclosed its first quarter 2022 portfolio, revealing that its top five trades for the quarter included a new position in Zoetis Inc. ( ZTS , Financial), a boost to its holding in Daiichi Sankyo Co. Ltd. ( TSE:4568 , Financial), the closure of its position in Elanco Animal Health Inc. ( ELAN , Financial) and reductions to its holdings in Bristol-Myers Squibb Co. ( BMY , Financial) and Anthem Inc. ( ANTM , Financial).

Vanguard Health Care Fund's Top 5 Trades in the 1st Quarter

AbbVie

Amgen

Baxter

Quest Diagnostics

Humana

Merck

As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. The post 7 Defensive Dividend Healthcare Stocks to Buy Now appeared first on InvestorPlace.

7 Defensive Dividend Healthcare Stocks to Buy Now

Zoetis Inc. (NYSE:ZTS ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Steve Frank - VP, IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Erin Wright - Morgan Stanley Christine Rains - William Blair Louise Chen - Cantor Nathan Rich - Goldman Sachs Michael Ryskin - Bank of America Jon Block - Stifel Balaji Prasad - Barclays Chris Schott - JPMorgan Steve Scala - Cowen Elliott Wilbur - Raymond James Operator Welcome to the First Quarter 2022 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.

Zoetis Inc. (ZTS) CEO Kristin Peck on Q1 2022 Results - Earnings Call Transcript

Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.

Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates

Zoetis (ZTS) delivered earnings and revenue surprises of 8.20% and 0.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Tops Q1 Earnings and Revenue Estimates

Zoetis beat first-quarter expectations Thursday and ZTS stock rose higher despite the company's unexpected guidance cut. The post Zoetis Delivers First-Quarter Beat, But Guidance Takes An Unexpected Hit appeared first on Investor's Business Daily.

Zoetis Delivers First-Quarter Beat, But Guidance Takes An Unexpected Hit

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE: ZTS) today reported its financial results for the first quarter of 2022 and updated its guidance for full year 2022 due to the negative impact of recent changes in foreign exchange rates. The updated guidance reflects the same operational growth rates for revenue and adjusted net income as stated in the company's previous guidance for 2022. The company reported revenue of $2.0 billion for the first quarter of 2022, an increase of 6% compared

Zoetis Announces First Quarter 2022 Results

Endo International

Intellia Therapeutics

Vir Biotechnology

Vertex Pharmaceuticals

Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.

Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More

Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.

Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Zoetis (ZTS)

In an inflationary environment, you want to be in companies with strong pricing power such as Zoetis. The company is well managed and has been growing at a very decent pace, it pays a small dividend but earnings growth has been solid.

Why You Might Want To Add Zoetis To Your Portfolio

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DrivenToCare--Today, the Zoetis Foundation announced that it will distribute $4.9 million during its first round of 2022 grants, supporting 20 initiatives based in 19 countries to help enable thriving professions and livelihoods for livestock farmers and veterinary professionals as well as relief efforts in Ukraine. Veterinarians, veterinary technicians and livestock farmers provide invaluable services to our communities, raising and caring for animals to be healthy and pro

Zoetis Foundation Announces First Round of 2022 Grants to Advance Farmer and Veterinarian Education, Livelihoods and Wellness

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 5, 2022. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2022 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentation

Zoetis to Host Webcast and Conference Call on First Quarter 2022 Financial Results

The global pet care market size increased to $232 billion in 2020 and is predicted to expand at a 6.1% compound annual growth rate (CAGR) between 2021 and 2027, according to Global Market insights. This is driven by the growing number of household pets, with one out of five U.S. households now owning a dog.

Zoetis: Growth and Market Dominance in the Pet Health Industry

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?

Why Is Zoetis (ZTS) Down 1.6% Since Last Earnings Report?

The stock price of Zoetis, an animal health company, has seen a 9% fall in a month, while it is down 6% in a week. The company reported upbeat Q4 results last month, with revenue of $2.0 billion and adjusted EPS of $1.00, beating the consensus estimates of $1.9 billion and $0.96, respectively.

Down 9% In A Month, Will Zoetis Stock Rebound?

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #CorporateSocialResponsibility--Zoetis has been named to Fast Company's list of Most Innovative Companies for 2022, ranking eighth in the corporate social responsibility category.

Zoetis Named One of Most Innovative Companies in 2022 by Fast Company

ResMed

Veeva Systems

The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions. The post 3 Beaten-Down Growth Stocks With More Than 50% Upside Potential appeared first on InvestorPlace.

3 Beaten-Down Growth Stocks With More Than 50% Upside Potential

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #earnings--Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2022 Animal Health Summit on Thursday, Feb. 24, 2022.

Zoetis to Participate in the Bank of America Securities 2022 Animal Health Summit

We upgrade our rating on Zoetis to Buy, after shares have fallen 22% from their peak, to below the level at our downgrade 7 months ago. Zoetis is a high-quality business capable of a 10%+ EPS CAGR long term. Its trailing P/E is now 41.2x, compared to 51.8x at our downgrade.

Zoetis: Upgrade To Buy After 22% Fall From Peak And Strong Q4

Zoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021.

Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates

Zoetis Inc. (ZTS) CEO Kristin Peck on Q4 2021 Results - Earnings Call Transcript

Animal health company Zoetis Inc.'s shares ZTS, -1.23% jumped 1.5% premarket Tuesday, after it beat estimates for the fourth quarter and offered upbeat revenue guidance for 2022. The company posted net income of $414 million, or 87 cents a share, for the quarter, up from $359 million, or 75 cents a share, in the year-earlier period.

Zoetis tops earnings estimates and offers upbeat revenue guidance, shares up 1.5% premarket

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis reports fourth quarter and full year 2021 financial results.

News for Zoetis Stock (ZTS)